Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jul 12.

Published in final edited form as: Am Heart J. 2018 Dec 20;209:79–87. doi: 10.1016/j.ahj.2018.11.012

Table I.

Characteristics of PWH and uninfected controls in HIVE-4CVD

	HIV+ (n = 5039)	Uninfected controls (n = 10,011)	P value

Average age, y	49.0	48.6	.06
Age 40–75 y, n (%)	3839 (76.2%)	7578 (75.7%)	.51
Sex, n male (%)	4166 (82.7%)	8262 (82.5%)	.824
Race			<.001
Black, n (%)	1572 (32.4%)	2771 (27.7%)
White, n (%)	1680 (34.6%)	3008 (30.1%)
Hispanic, n (%)	172 (3.5%)	461 (4.6%)
Other/unknown, n (%)	1615 (32.1%)	3771 (37.7%)
HTN diagnosis, n (%)	1674 (33.2%)	1775 (17.7%)	<.001
DM diagnosis, n (%)	463 (9.2%)	541 (5.4%)	<.001
TC, baseline, mg/dL	171.89	182.5	<.001
HDL, baseline, mg/dL	39.74	45.80	<.001
TG, baseline, mg/dL	161.13	126.98	<.001
Statin therapy, n (%)	1017 (20.2%)	813 (8.1%)	<.001
Nadir CD4, cells/mm³	276.41	n/a
ART, n (%)	4251 (84.7%)	n/a
Protease inhibitor, n (%)	2363 (46.9%)	n/a

HTN, hypertension.